Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant Novavax XBB.1.5 and PCV20 vaccination in adults aged 60 years or older
2022-004118-12Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of NVX-CoV2373 and Prevnar 20 in coronavirus disease 2019 (COVID-19) and pneumococcal disease (4 arms), sponsored by Medical University of Vienna. Primary endpoint: Anti-RBD antibody levels. Started Jan 2023; status: completed.
02
Drugs
NVX-CoV2373Prevnar 20
03
Conditions
coronavirus disease 2019 (COVID-19)pneumococcal disease
Beyond the preview
Go deeper on 2022-004118-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004118-12.